52177-49-8

Upstream product

• 75-44-5 phosgene 
• 1457-06-3 4-[N,N-bis(2-chloroethyl)amino]phenol hydrochloride 
• 17794-35-3 benzyl-p-(bis-2-chloroethylamino)phenyl ester 
• 101582-69-8 4--O-benzylphenol 
• 2198-51-8 p-phenol 
• 1204-69-9 4-[bis(2-chloroethyl)amino]phenol 

Downstream Products

• 52177-50-1 4-({4-[Bis-(2-chloro-ethyl)-amino]-phenoxycarbonyl}-methyl-amino)-benzoic acid methyl ester 
• 156078-80-7 (S)-2-{4-[Bis-(2-chloro-ethyl)-amino]-phenoxycarbonylamino}-pentanedioic acid dibenzyl ester 
• 191352-32-6 (2S,3S,4S,5R,6S)-6-[2-({4-[Bis-(2-chloro-ethyl)-amino]-phenoxycarbonyl}-methyl-amino)-4-nitro-phenoxy]-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid methyl ester 
• 191352-27-9 (2S,3S,4S,5R,6S)-6-[2-({4-[Bis-(2-chloro-ethyl)-amino]-phenoxycarbonyl}-methyl-amino)-4-nitro-phenoxy]-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid 
• 156078-79-4 4-[N,N-bis(2-chloroethyl)amino]-phenoxycarbonyl-L-glutamic acid 

Relevant academic research and scientific papers

Prodrugs for the therapy of tumors and inflammatory disorders

Compounds of the formula Iglycosyl-Y[--C( Y)--X--] p --W(R) n --Z--C( Y)-active compound (I)are described which are suitable for the treatment of carcinomatous diseases, autoimmune diseases and chronic inflammatory diseases such as rheumatoid arthritis.

Glucuronide prodrugs of hydroxy compounds for antibody directed enzyme prodrug therapy (adept): A phenol nitrogen mustard carbamate

A prodrug consisting of a β-D-glucuronic acid linked to a self-immolative spacer (a N-(ortho-hydroxyphenyl)-N-methylcarbamate) and a phenolic nitrogen mustard was synthesised. As this prodrug was easily cleaved by a β-glucuronidase enzyme and displayed lo

New mustard prodrugs for antibody-directed enzyme prodrug therapy: Alternatives to the amide link

Antibody-directed enzyme prodrug therapy (ADEPT) is a two-step approach for the treatment of cancer which seeks to generate a potent cytotoxic agent selectively at a tumor site. In this work described the cytotoxic agent is generated by the action of an enzyme CPG2 on a relatively nontoxic prodrug. The prodrug 1 currently on clinical trial is a benzamide and is cleaved by CPG2 to a benzoic acid mustard drug 1a. We have synthesized a series of new prodrugs 3-8 where the benzamide link has been replaced by, for example, carbamate or ureido. Some of these alternative links have been shown to be good substrates for CPG2 and therefore new candidates for ADEPT. The active drugs 3a and 4a derived from the best of these prodrugs are potent cytotoxic agents (1-2 μM) some 100 times more than 1a. The prodrugs 3 and 4 are some 100-200-fold less cytotoxic, in a proliferating cell assay, than their corresponding active drugs 3a and 4a.